Author Affiliations: Duke Clinical Research
Institute, Durham, NC.
In this issue of JAMA, 2 articles from the
Clinical Trial of Reviparin and Metabolic Modulation in Acute Myocardial Infarction
Treatment Evaluation (CREATE) greatly enhance the knowledge base for the treatment
of acute ST-segment elevation myocardial infarction (STEMI).1,2 Yet,
as with all good clinical trials, this study raises new questions and perspectives
that deserve further consideration.
Califf RM. Simple Principles of Clinical Trials Remain Powerful. JAMA. 2005;293(4):489–491. doi:10.1001/jama.293.4.489